Mergers & Acquisitions
Filter News
Found 20,595 articles
-
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business Combination
11/10/2022
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and Vickers Vantage Corp.
-
PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company
11/9/2022
PolarityTE, Inc. confirmed that on November 1, 2022, it received an unsolicited, non-binding offer from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash.
-
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
11/8/2022
Avenue Therapeutics, Inc. today announced the closing of the acquisition of Baergic Bio, Inc. (“Baergic Bio”) pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech, Inc.
-
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
11/8/2022
ARS Pharmaceuticals, Inc. announced the closing of its merger with Silverback Therapeutics, Inc.
-
CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma
11/8/2022
CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related medicine, announced today that it has acquired a controlling interest in TaGeza Biopharmaceuticals Ltd.
-
Bruker Announces Acquisition of Inscopix for Neuroscience Research
11/8/2022
Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Inscopix, Inc., a neuroscience pioneer and market leader of miniaturized microscopes, known as miniscopes, for freely moving animal brain imaging.
-
Leica Biosystems Acquires Cell IDx, Moving its Multiplexing Menu Forward with Ready-to-Use, Pre-Kitted Formulations
11/8/2022
Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging, has acquired Cell IDx, Inc., a leader in multiplexed tissue profiling.
-
Eye specialist Oyster Point Pharma announced is being acquired by Viatris Inc. after Oyster’s board of directors unanimously signed off on the deal, Oyster Point announced Monday.
-
Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million
11/7/2022
Avalo Therapeutics, Inc., announced it entered into a purchase agreement to sell its economic rights to future payments for previously out-licensed assets including AVTX-007, AVTX-501, and AVTX-611 to ES Therapeutics, LLC in exchange for $5.0 million.
-
RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa Is an Invited Speaker at the 5th Meridian Drug Discovery Summit
11/7/2022
RespireRx Pharmaceuticals Inc. is pleased to announce that Dr. Arnold Lippa, Chief Scientific Officer, Executive Chairman of the Board and Interim President and Interim Chief Executive Officer is an invited speaker and panel moderator at the 5th Meridian Drug Discovery Summit, being held November 7th and 8th at the Embassy Suites by Hilton Logan Airport, Boston MA.
-
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris
11/7/2022
Oyster Point Pharma, Inc., announced that it has entered into a definitive agreement under which Viatris Inc., a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
-
Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event
11/7/2022
Viatris Inc. announced that it intends to create an ophthalmology franchise by acquiring Oyster Point Pharma and Famy Life Sciences and that it will provide a strategic update on its February 2022 Investor Event in a conference call and live webcast today at 8:30 a.m. ET.
-
Anumana Acquires NeuTrace, Establishing a Comprehensive Electrophysiology Deep-Learning Development Platform and Product Pipeline
11/7/2022
Anumana, an AI-driven health technology company and portfolio company of nference, announced today it has acquired NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP).
-
Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company
11/7/2022
Fulgent Genetics, Inc. announced that it has completed an acquisition of Fulgent Pharma Holdings, Inc., an independent clinical-stage, therapeutics development company focused on the development of innovative cancer treatments.
-
Reaction Biology and Vyant Bio Announce Closing of Definitive Agreement to Acquire U.S. Operations of Vyant Bio, Inc. Subsidiary
11/3/2022
Reaction Biology Corporation (“Reaction”) and Vyant Bio, Inc. (“Vyant Bio”) (Nasdaq: VYNT) today announced that the companies have closed on a definitive agreement for Reaction to acquire Vyant Bio’s subsidiary vivoPharm LLC, located in Hershey, Pennsylvania.
-
Evotec Completes Acquisition of Central Glass Germany
11/3/2022
Evotec SE announced that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in August 2022, has been completed.
-
San Diego-based Arcturus Therapeutics signed a strategic collaboration and licensing deal with CSL Seqirus to help develop and commercialize vaccines.
-
OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company
11/2/2022
OrsoBio, Inc. today announced its acquisition of an ACMSD inhibitor program from Mitobridge, an Astellas Company.
-
OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals
11/2/2022
OrsoBio, Inc. today announced its acquisition of assets relating to the Liver X Receptor (LXR) inverse agonist program from Phenex Pharmaceuticals, including lead candidate TLC-2716 and associated intellectual property.
-
Medical Manufacturing Technologies (MMT) Acquires Confluent Medical Equipment Line
11/2/2022
Medical Manufacturing Technologies (MMT) announced the purchase of Confluent Medical Technologies' equipment manufacturing group, which includes their balloon forming equipment manufacturing as well as their testing and catheter manufacturing equipment capabilities.